Evidence map›Paper›PMID 38681979›Full record

ArticleCrohn's & colitis 3602024

Effectiveness and Safety of Ustekinumab for Ulcerative Colitis: A Brazilian Multicentric Observational Study.

Rogério Serafim Parra, Júlio Maria Fonseca Chebli, Matheus Freitas Cardoso de Azevedo, Liliana Andrade Chebli, Gilmara Pandolfo Zabot, Ornella Sari Cassol, Renata de Sá Brito Fróes, Genoile Oliveira Santana, Márcio Lubini, Daniela Oliveira Magro and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Crohn's & colitis 360, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Observational
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Rogério Serafim ParraDepartment of Surgery and Anatomy, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.ORCID https://orcid.org/0000-0002-5566-9284
Júlio Maria Fonseca ChebliDivision of Gastroenterology, Department of Medicine, Inflammatory Bowel Disease Center, Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil.ORCID https://orcid.org/0000-0003-1527-0663
Matheus Freitas Cardoso de AzevedoDepartment of Gastroenterology, University of São Paulo School of Medicine, São Paulo, Brazil.ORCID https://orcid.org/0000-0001-5487-9418
Liliana Andrade ChebliDivision of Gastroenterology, Department of Medicine, Inflammatory Bowel Disease Center, Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil.ORCID https://orcid.org/0000-0002-7875-1475
Gilmara Pandolfo ZabotDepartment of Colon and Rectum Surgery, Moinhos de Vento Hospital, Feevale University, Porto Alegre, Brazil.ORCID https://orcid.org/0000-0002-1253-4945
Ornella Sari CassolDepartment of Colorectal Surgery, Hospital de Clínicas de Passo Fundo, Atitus Medical School, Rio Grande do Sul, Brazil.ORCID https://orcid.org/0000-0003-0867-6593
Renata de Sá Brito FróesDepartment of Gastroenterology and Endoscopy, Gastromed, Rio de Janeiro, Brazil.ORCID https://orcid.org/0000-0003-3256-4698
Genoile Oliveira SantanaDepartment of Life Sciences, State University of Bahia, Salvador, Bahia, Brazil.ORCID https://orcid.org/0000-0001-5936-9791
Márcio LubiniDepartment of Surgery, Passo Fundo University, Rio Grande do Sul, Brazil.ORCID https://orcid.org/0000-0003-2779-7841
Daniela Oliveira MagroDepartment of Surgery, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.ORCID https://orcid.org/0000-0002-8180-6254
Marcello ImbriziDepartment of Surgery, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.ORCID https://orcid.org/0000-0001-5397-0084
Antonio Carlos da Silva MoraesInternal Medicine Department, Hospital Copa D´Or, Rio de Janeiro, Brazil.ORCID https://orcid.org/0000-0002-5533-5401
Fabio Vieira TeixeiraDepartment of Gastroenterology, Gastrosaúde Clinic, Marilia, São Paulo, Brazil.ORCID https://orcid.org/0000-0002-8915-7279
Antonio José Tiburcio Alves JuniorDepartment of Surgery, PUC-Campinas Medical School, PUC-Campinas University, Campinas, São Paulo, Brazil.ORCID https://orcid.org/0000-0002-6795-8526
Newton Luiz Tricarico Gasparetti JuniorDepartment of Surgery, Hospital Vivalle Rede Dor, São José dos Campos, São Paulo, Brazil.ORCID https://orcid.org/0009-0002-1015-9130
Sandro da Costa FerreiraDepartment of Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.ORCID https://orcid.org/0000-0001-7698-6599
Natália Sousa Freitas QueirozHealth Sciences Graduate Program, Pontifícia Universidade Católica do Paraná (PUCPR), Curitiba, Brazil.ORCID https://orcid.org/0000-0003-2857-0825
Paulo Gustavo KotzeHealth Sciences Graduate Program, Pontifícia Universidade Católica do Paraná (PUCPR), Curitiba, Brazil.ORCID https://orcid.org/0000-0002-9632-6691
Omar FéresDepartment of Surgery and Anatomy, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.ORCID https://orcid.org/0000-0003-3593-0526

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Real-world data on the effectiveness and safety of ustekinumab (UST) in ulcerative colitis (UC) are lacking in Latin America. In this study, we aimed to describe the effectiveness and safety of UST in a real-world multicenter cohort of Brazilian patients with UC. Methods: We conducted a multicenter retrospective observational cohort study, including patients with moderate-to-severe UC (total Mayo score 6-12, with an endoscopic subscore of 2 or 3) who received UST. The co-primary endpoints were clinical remission, defined as a total Mayo score ≤2 at 1 year, with a combined rectal bleeding and stool frequency subscore of ≤1, and endoscopic remission (endoscopic Mayo subscore of 0) within 1 year from baseline. Secondary endpoints included clinical response between weeks 12 and 16, endoscopic response within 1 year of starting UST, steroid-free clinical remission at week 52, and biochemical remission at week 52. We also evaluated UST treatment persistence and safety. Results: A total of 50 patients were included (female, Conclusions: In this real-world cohort of difficult-to-treat UC patients, UST was associated with improvements in clinical, biochemical, and endoscopic outcomes. The safety profile was favorable, consistent with the known profile of UST.

Indexed as

biological therapyinflammatory bowel diseasereal worldulcerative colitisustekinumab

Identifiers

PMID38681979
PMCPMC11053358

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.